Kif18a inhibitors
US-2020239441-A1 · Jul 30, 2020 · US
Macrocyclic compounds and methods of use
US12570672B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12570672-B2 |
| Application number | US-202418614911-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 25, 2024 |
| Priority date | Nov 14, 2022 |
| Publication date | Mar 10, 2026 |
| Grant date | Mar 10, 2026 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present disclosure provides compounds useful for the inhibition of KRAS G12D, G12V, G12A, G12S, G13D, Q61H, Q61L or G12C. The compounds have a general Formula I′: wherein the variables of Formula I′ are defined herein. This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, cancer.
First claim
Opening claim text (preview).
What is claimed is: 1 . A compound, wherein the compound is: Compound or or a pharmaceutically acceptable salt thereof. 2 . A compound, wherein the compound is or a pharmaceutically acceptable salt thereof. 3 . The compound or salt of claim 1 , wherein the compound is 4 . The compound or salt of claim 1 , wherein the compound is 5 . The compound or salt of claim 1 , wherein the compound is 6 . The compound or salt of claim 1 , wherein the compound is 7 . The compound or salt of claim 1 , wherein the compound is 8 . The compound or salt of claim 1 , wherein the compound is 9 . The compound or salt of claim 1 , wherein the compound is 10 . The compound or salt of claim 1 , wherein the compound is 11 . The compound or salt of claim 1 , wherein the compound is 12 . A compound, wherein the compound is: Compound
Assignees
Inventors
Classifications
in which the condensed system contains four or more hetero rings · CPC title
in which the condensed system contains four or more hetero rings · CPC title
- C07D471/22Primary
in which the condensed systems contains four or more hetero rings · CPC title
having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine · CPC title
having two nitrogen atoms, e.g. dilazep · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12570672B2 cover?
- The present disclosure provides compounds useful for the inhibition of KRAS G12D, G12V, G12A, G12S, G13D, Q61H, Q61L or G12C. The compounds have a general Formula I′: wherein the variables of Formula I′ are defined herein. This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, cancer.
- Who is the assignee on this patent?
- Amgen Inc
- What technology area does this patent fall under?
- Primary CPC classification C07D471/22. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Mar 10 2026 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 5 related publications on this page (citations in our corpus or others sharing the same primary CPC).